comprehensive -WSS

comprehensive

author：Wikipedia 2025-10-01 02:12:00 - browse：96727

Boxes of Wegovy — pharma coverage from STAT — Carsten Snejbjerg/Bloomberg

LONDON — The investment arm of Novo Nordisk’s parent foundation is buying drug manufacturer Catalent in a $16.5 billion deal, an acquisition that will give Novo additional sites as it builds up production of its booming obesity and diabetes drugs.

Under the deal, Novo Holdings is purchasing Catalent, a major contract development and manufacturing company with more than 50 sites globally. In turn, Novo Nordisk is buying three of Catalent’s fill-finish sites from the investment group for $11 billion. Novo Holdings manages the assets of the Novo Nordisk Foundation, which has a controlling stake in the pharmaceutical company.

Catalent has been involved in the production of Novo’s obesity treatment Wegovy. With the agreement, Novo will pick up sites that focus on filling drugs in Italy, Brussels, and Bloomington, Ind. All have already been doing work for Novo.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： Change Healthcare payments predicted restored March 15

knowledge

focus

WSS

ASCO: AstraZeneca's Tagrisso greatly slowed some lung cancers

In his State of the Union, Biden takes clear aim at 'Big Pharma'

Change Healthcare cyberattack prompts Medicare loan program

The drug industry has found itself all alone in Washington

HIV drugs protect against transmission, even in unprotected sex

Readout LOUD podcast: Venture capital turmoil, obesity drug competition

leisure time

comprehensive

focus

Jerome Adams on the need for new antivirals for Covid

NEJM study link tiny plastics in blood vessels to heart problems

Alkermes shareholders re

Amylyx ALS drug fails large clinical trial

Virginia high school admissions case could be legal follow

The Readout: Amylyx, Alumis, and Lundbeck drug updates

Medical leaders decry Supreme Court decision on affirmative action

ASCO 2024: 'Reassuring' Corbus data on ADC bladder cancer drug

DIEP, the 'gold standard' of breast reconstruction, is under threat

CDC marks new Covid

entertainment

ASCO: AstraZeneca's hat trick, and palliative care's spotlight

Change Healthcare cyberattack prompts Medicare loan program

A deep dive into Applied Therapeutics’ data, and questions on Cassava

ASCO 2024: 'Reassuring' Corbus data on ADC bladder cancer drug

The problem with charging patients to message their doctors

Readout Newsletter: Acadia, Eli Lilly, Madrigal Pharma updates

knowledge

focus

focus

knowledge